Table 1.
Clinical characteristics of 2 different treatment groups
| Treatment groups |
p value | ||
|---|---|---|---|
| curative treatment | TACE | ||
| Patients, N | 71 | 97 | |
| Age | |||
| Mean ± SD | 55±12 | 64±12 | <0.0001a |
| Sex | |||
| Male | 60 | 65 | 0.01b |
| Female | 11 | 32 | |
| BCLC stage | |||
| 0 | 22 | 7 | 0.0001b |
| A | 49 | 90 | |
| Initial curative treatment | |||
| Surgery | 64 | 0 | |
| PEI | 2 | 0 | |
| RFA | 6 | 0 | |
| Tumors, n | 0.03c | ||
| 1 | 67 | 80 | 1 vs. >1 |
| 2 | 3 | 12 | |
| 3 | 1 | 5 | |
BCLC, Barcelona Clinic Liver Cancer; TACE, transcatheter arterial chemoembolization; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation.
a
The Wilcoxon rank-sum test was used.
b
Fisher's exact test was used.
c
The number of tumors was grouped as 1 and >1, and Fisher's exact test was used for statistical comparison.